FARICIMAB

UNII:	QC4F7FKK7I
Formula:
Preferred Substance Name:	FARICIMAB

1607793-29-2
FARICIMAB [INN]
FARICIMAB [JAN]
FARICIMAB [USAN]
FARICIMAB [WHO-DD]
FARICIMAB SVOA [WHO-DD]
FARICIMAB-SVOA
IMMUNOGLOBULIN G1, ANTI-(HUMAN ANGIOPOIETIN 2) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER WITH IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL LIGHT CHAIN
IMMUNOGLOBULIN G1-KAPPA/LAMBDA WITH DOMAIN CROSSOVER, ANTI-(HOMO SAPIENS-VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A, VASCULAR PERMEABILITY FACTOR, VPF)) AND ANTI-(HOMO SAPIENS-ANGIOPOIETIN-2 (ANG-2)), HUMANIZED AND HOMO SAPIENS MONOCLONAL ANTIBODY, BISPECIFIC.GAMMA.1 HEAVY CHAIN ANTI-VEGF-A (1-453) (HUMANIZED VH (HOMO SAPIENS IGHV3-30*02 (76%) (IGHD)-IGHJ4*01 (93%)) (8.9.16) (1-123) -HOMO SAPIENS IGHG1*01 (CH2(L4>A(240), L5>A(241), I23>A(259), H80>A(316), P99>G(335)), CH3(S14>C(360), T26>W(372), H95>A(441))) (124-453)), (226-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN ANTI-VEGF-A (1'-214') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-16*01 (87%) IGKJ1*01)(6.3.9) (1'-107') -HOMO SAPIENS IGKC*01 (108'-214')).GAMMA.1-.KAPPA. HEAVY CHAIN ANTI-ANG-2 (1''-463'') (HOMO SAPIENS VH (IGHV1-2*02(IGHD)-IGHJ3*02) (8.8.22) (1''-129'') -HOMO SAPIENS IGKC*01 (R1>A(130''),T2>S(131'')) (130''-236'') -HOMO SAPIENS IGHG1*01 (DEL-CH1, HINGE-(6-15)>(237''-246''), CH2(L4>A(250''), L5>A(251''), I23>A(269''), H80>A(326''), P99>G(345'')), CH3(Y9>C(365''), T26>S(382''), L28>A(384''), Y67>V(423''), H95>A(451''))) (237''-463'') (236''-213''')-DISULFIDE WITH .LAMBDA.-.GAMMA.-LIGHT CHAIN ANTI-ANG-2 (1'''-213''') (HOMO SAPIENS V-LAMBDA (IGLV3-21*02IGLJ3*02)(6.3.11) (1'''-110''') -HOMO SAPIENS IGHG1*01(CH1-HINGE-(1-5)) (111'''-213'''))DIMER (232-242''-235-245'':360-365'')-TRISDISULFIDE
RG7716
RG-7716
RG-7716 (ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR/ANTI-ANGIOPOIETIN 2 BISPECIFIC ANTIBODY)
RO6867461
RO-6867461
VABYSMO
Y8HA1I28D3

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

FARICIMAB

Synonyms and Mappings

Resources